Abstract

Despite progress in conventional treatment methods for colon cancer, it remains the fourth leading cause of cancer-related deaths in the world. Therefore, more effective new treatment strategies for colon cancer are needed. Silver nanoparticles (AgNPs) synthesized using plant extracts have shown therapeutic applications and make it to be a good anti-cancer candidates. The aim of this study was to evaluate the anti-metastatic and anti-cancer activity of biosynthesized silver nanoparticles from Rosa canina extract on the human colon adenocarcinoma cell line HT29. The biosynthesis of AgNPs was carried out using Rosa canina extract. R-AgNPs were characterized by techniques such as UV-vis spectrophotometer and scaining electron microscopy (SEM). HT29 cells were incubated with different concentrations of AgNPs (0-20 µg/mL) for 48 h. The cytotoxic activity of the synthesized R-AgNPs against human colon adenocarcinoma cells HT29 was investigated by MTT assay and the IC50 value were found to be 7,89 µg/mL at 48 h incubation. Anti-metastatic potential of R-AgNPs were determined on HT29 cells using scratch assay. R-AgNPs induced a significant decrease of cell motility in dose-dependent manner. In conlusion, these findings suggest that the biosynthesized AgNPs may be promising new therapeutic agents for the treatment of human colon cancer.

Highlights

  • Colorectal cancer, known as colon cancer, is a cancer is the third leading cause of cancer-related type of cancer that begins in the colon

  • The surface nature of the R-AgNPs were determined by scaining electron microscopy (SEM). (Figure 1C)

  • It was seen that according to Energy Dispersive X-ray Spectroscopy (EDX), there were peaks of Ag metal in the elemental composition of R-AgNPs (Figure 1D)

Read more

Summary

Objectives

The aim of this study was to evaluate the anti-metastatic and anti-cancer activity of biosynthesized silver nanoparticles from Rosa canina extract on the human colon adenocarcinoma cell line HT29

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.